詳細検索はこちら

劉 大革 リュウ ダグ

所属
医学部
医学科
職名助教
Last Updated :2020/09/17

研究者基本情報

基本情報

    科研費研究者番号:30314941

学歴

  •  - 1999年, 香川医科大学
  •  - 1999年, 香川医科大学, 医学研究科

学位

  • 医学博士, 香川医科大学
  • 医学学士, 錦州医学院
  • Bachelor of Medicine, Jinzhou Medical University

所属学協会

  • 日本癌学会
  • 日本胸部外科学会
  • 日本呼吸器外科学会
  • 日本外科学会
  • Japanese Cancer Association
  • The Japanese Association for Thoracic Surgery
  • The Japanese Association for Chest Surgery (JACS)
  • Japan Surgical Sociaty

経歴

  •   1999年, - 香川大学 医学部 呼吸器外科, 助教
  •   1999年, - Department of Thoracic Surgery, Faculty of Medicine, Kagawa University, Assistant Professor
  •   1989年,  - 1994年, 本鋼胸科医院
  •   1989年,  - 1994年, Department of Thoracic Surgery, Chest Hospital of Benxi Iron & Steel Co., Stuff

研究活動情報

研究分野

  • ライフサイエンス / 呼吸器外科学
  • ライフサイエンス / 心臓血管外科学
  • ライフサイエンス / 外科学一般、小児外科学

研究キーワード

    外科学一般, General surgery

論文

  • Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer, Shoko Norimura, Keiichi Kontani, Takako Kubo, Shin-Ichiro Hashimoto, Chisa Murazawa, Koichiro Kenzaki, Dage Liu, Masafumi Tamaki, Fuminori Aki, Kazumasa Miura, Kiyoshi Yoshizawa, Akira Tangoku, Hiroyasu Yokomise, Journal of Cancer Research and Therapeutics, Journal of Cancer Research and Therapeutics, 14, (2) 409 - 415,   2018年01月01日, [査読有り]
  • Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer, Dage Liu, Nariyasu Nakashima, Jun Nakano, Shintaro Tarumi, Natsumi Matsuura, Takayuki Nakano, Kazuhito Nii, Yoshimasa Tokunaga, Tetsuhiko Go, Hiroyasu Yokomise, ANTICANCER RESEARCH, ANTICANCER RESEARCH, 37, (5) 2501 - 2507,   2017年05月, [査読有り]
  • Vimentin Regulates Invasiveness and Is a Poor Prognostic Marker in Non-small Cell Lung Cancer, Akira Tadokoro, Nobuhiro Kanaji, Dage Liu, Hiroyasu Yokomise, Reiji Haba, Tomoya Ishii, Takehiro Takagi, Naoki Watanabe, Nobuyuki Kita, Norimitsu Kadowaki, Shuji Bandoh, ANTICANCER RESEARCH, ANTICANCER RESEARCH, 36, (4) 1545 - 1551,   2016年04月, [査読有り]
  • Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells, Yoshimasa Tokunaga, Dage Liu, Jun Nakano, Xia Zhang, Kazuhito Nii, Tetsuhiko Go, Cheng-Long Huang, Hiroyasu Yokomise, EUROPEAN JOURNAL OF CANCER, EUROPEAN JOURNAL OF CANCER, 51, (16) 2480 - 2489,   2015年11月, [査読有り]
  • G Protein-Coupled Receptor 87 (GPR87) Promotes Cell Proliferation in Human Bladder Cancer Cells, Xia Zhang, Dage Liu, Yushi Hayashida, Homare Okazoe, Takeshi Hashimoto, Nobufumi Ueda, Mikio Sugimoto, Yoshiyuki Kakehi, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 16, (10) 24319 - 24331,   2015年10月, [査読有り]
  • Engineering a well-ordered, functional protein-gold nanoparticle assembly, Jasmina C. Cheung-Lau, Dage Liu, Katherine W. Pulsipher, Weiren Liu, Ivan J. Dmochowski, JOURNAL OF INORGANIC BIOCHEMISTRY, JOURNAL OF INORGANIC BIOCHEMISTRY, 130,   2014年01月, [査読有り]
  • Expression and role of GPR87 in urothelial carcinoma of the bladder., Homare Okazoe, Xia Zhang, Dage Liu, Shinsuke Shibuya, Nobufumi Ueda, Mikio Sugimoto, Yoshiyuki Kakehi, International journal of molecular sciences, International journal of molecular sciences, 14, (6) 12367 - 79,   2013年06月10日, [査読有り]
  • Wnt3 gene expression promotes tumor progression in non-small cell lung cancer, Nariyasu Nakashima, Dage Liu, Cheng-long Huang, Masaki Ueno, Xia Zhang, Hiroyasu Yokomise, LUNG CANCER, LUNG CANCER, 76, (2) 228 - 234,   2012年05月, [査読有り]
  • [Prognosis of surgically treated large cell neuroendocrine carcinoma]., Natsumi Matsuura, Nariyasu Nakashima, Hitoshi Igai, Shintarou Tarumi, Sung-Soo Chang, Noriyuki Misaki, Dage Liu, Tetsuhiko Go, Shinya Ishikawa, Cheng-Long Huang, Hiroyasu Yokomise, Kyobu geka. The Japanese journal of thoracic surgery, Kyobu geka. The Japanese journal of thoracic surgery, 64, (3) 187 - 90,   2011年03月, [査読有り]
  • Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer, Nariyasu Nakashima, Cheng-Long Huang, Dage Liu, Masaki Ueno, Hiroyasu Yokomise, INTERNATIONAL JOURNAL OF ONCOLOGY, INTERNATIONAL JOURNAL OF ONCOLOGY, 37, (3) 687 - 694,   2010年09月, [査読有り]

Misc

  • Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer, 劉大革, 中島成泰, 中野淳, 垂水晋太郎, 松浦奈都美, 中野貴之, 新居和人, 徳永義昌, 呉哲彦, 横見瀬裕保, Dage Liu, Nariyasu Nakashima, Jun Nakanon, Shintaro Tarumi, Natsumi Matsuura, Takayuki Nakano, Kazuhito Nii, Yoshimasa Tokunaga, Tetsuhiko Go, Hiroyasu Yokomise, Anticancer Res., 37, (5), 5597-5602,   2017年04月, [査読有り]
  • G Protein-Coupled Receptor 87 (GPR87) Promotes Cell Proliferation in Human Bladder Cancer Cells, Zhang X, Liu D, Hayashida Yushi, Okazoe H, Hashimoto T, Ueda N, Sugimoto M, Kakehi Y(Zhang Xia, Liu Dage, Hayashida Yushi, Okazoe H, HASHIMOTO Takeshi, Ueda N, Sugimoto M, Kakehi Y, Int J Mol Sci., 14, (10), 24319-31,   2015年10月, [査読有り]
  • Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells, Tokunaga Hiryoyasu, LIU Dage, NAKASHIMA Nariyasu, Zhang Xia, NII Kazuhito, GO Tetsuhiko, HUANG Cheng-long, YOKOMISE Hiroyasu, Eur J Cancer, 51, (16), 2480-9,   2015年09月, [査読有り]
  • Overexpression of G protein-coupled receptor 87 correlates with poorer tumor differentiation and higher tumor proliferation in non-small-cell lung cancer, KAZUHITO NII, YOSHIMASA TOKUNAGA, DAGE LIU, XIA ZHANG, JUN NAKANO, SHINYA ISHIKAWA, YOSHIYUKI KAKEHI, REIJI HABA, YOKOMISE HIROYASU, Mol Clin Oncol., 2, (4), 539-544,   2014年07月, [査読有り]
  • Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer., Yokomise H, Liu D, Ishikawa S, Go T, Gotoh M, Okuda M, Tarumi S, Kasai Y, Matsuura N, Anticancer Res., 33, (12), 5597-5602,   2013年12月, [査読有り]
  • Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder., Okazoe H, Zhang X, Liu D, Shibuya S, Ueda N, Sugimoto M, Kakehi Y, Int J Mol Sci., 14, (6), 12367-79,   2013年06月, [査読有り]
  • Biomarkers as Prognostic Factors for cN2 or 3 Non-small Cell Lung Cancer Treated by Induction Chemoradiotherapy and Surgery, YOKOMISE Hiroyasu, LIU Dage, CHANG SunSoo, GO Tetsuhiko, ISHIKAWA Shinya, MISAKI Noriyuki, NAKASHIMA Nariyasu, Anticancer Research, 33, (3), 1107-15,   2013年03月, [査読有り]
  • Wnt3 gene expression promotes tumor progression in non-small cell lung cancerr, NAKASHIMA Nariyasu, LIU Dage, HUANG Cheng-long, UENO Masaki, ZHANG Xia, YOKOMISE Hiroyasu, Lung Cancer, 76, (2), 228-34,   2012年05月, [査読有り]
  • Adenoviral vector expressing short hairpin RNA targeting Wnt2B has an effective antitumour activity against Wnt2B2-overexpressing tumours, Dage Liu, Kyuichi Kadota, Masaki Ueno, Nariyasu Nakashima, Hiroyasu Yokomise, Cheng-long Huang, EUROPEAN JOURNAL OF CANCER, 48, (8), 1208 - 1218,   2012年05月, [査読有り]
    Background: The Wnt family encodes multi-functional signalling glycoproteins regulating various normal and pathological processes including tumourigenesis. Wnt2B overexpression is thought to affect tumour progression through the activation of the canonical Wnt pathway. Method: Experimental studies were conducted using a Wnt2B-inhibiting vector to establish gene therapy against Wnt2B2-overexpressing tumours. A replication-deficient recombinant adenoviral vector expressing short hairpin RNA targeting Wnt2B (Ad-shWnt2B) was constructed. Three Wnt2B2-overexpressing human tumour cells, including A549 cells, Hela cells and PANC1 cells, were used. Thereafter, cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Next, a human tumour xenograft model in nude mice was prepared by subcutaneously implanting tumours derived from A549 cells. Ad-shWnt2B was administered via intratumoural injection every 4 days. Results: First, immunohistochemical studies revealed that high levels of Wnt2B expression appeared in proliferative normal tissues and many human tumour tissues. Furthermore, the Wnt2B2 gene expression was associated with c-Myc and survivin expressions in human lung cancer. Transduction with Ad-shWnt2B effectively downregulated the Wnt2B2 expression in all the three Wnt2B2-overexpressing tumour cells (p < 0.0001). The transduction with Ad-shWnt2B significantly reduced the percentage of viable cells in all the Wnt2B2-overexpressing tumour cells (p < 0.005). In addition, transduction with Ad-shWnt2B significantly downregulated c-Myc and survivin in A549 cells (p < 0.005). Furthermore, the treatment with Ad-shWnt2B exerted a significant antitumour effect against the Wnt2B2-overexpressing A549 xenografts by inducing apoptosis (p < 0.01). Conclusions: Cancer gene therapy using an adenoviral vector expressing short hairpin RNA (shRNA) against Wnt2B was, therefore, found to have a strong antitumour effect against Wnt2B2-overexpressing tumours. (C) 2011 Elsevier Ltd. All rights reserved.
  • Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors, Kyuichi Kadota, Cheng-Long Huang, Dage Liu, Hiroyaseu Yokomise, Reiji Haba, Hiromi Wada, INTERNATIONAL JOURNAL OF ONCOLOGY, 38, (2), 355 - 363,   2011年02月, [査読有り]
    High levels of intratumoral thymidylate synthase (TS) expression are associated with resistance to 5-fluorourcil (5-FU). In order to establish a new treatment method for 5-FU-resistant tumors, the efficacy of gene therapy was investigated using an adenoviral vector expressing short hairpin RNA (shRNA) targeting TS. A replication-deficient recombinant adenoviral vector expressing shRNA targeting TS was constructed under the control of the human U6 promoter (Ad-shTS). Three 5-FU-resistant cancer cell lines, DLD-1/5FU, KM12C/5FU and NUGC-3/5FU, were used. Transduction with Ad-shTS effectively downregulated TS expression in all three 5-FU-resistant tumor cells. MTT assays demonstrated that treatment with Ad-shTS significantly inhibited the growth of all three 5-FU-resistant tumor cells. Furthermore, combined treatment with Ad-shTS and 5-FU demonstrated significantly greater inhibition of tumor cell growth in comparison to 5-FU treatment alone and Ad-shTS treatment alone. S-1, a combination of tegafur, gimeracil and oteracil potassium, was used for the 5-FU treatment by in vivo experiments. The combined treatment of Ad-shTS and S-1 was found to have the strongest antitumor effect against 5-FU-resistant DLD-1/5FU xenografts in nude mice in comparison to S-1 treatment alone and Ad-shTS treatment alone. Furthermore, the apoptotic index in tumors treated with combined Ad-shTS and S-1 was significantly higher in comparison to that in tumors treated with S-1 alone and that in tumors treated with Ad-shTS alone. Consequently, the combined treatment of the TS-inhibiting adenoviral vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
  • The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer, KADOTA Kyuuichi, HUANG Cheng-long, LIU Dage, NAKASHIMA Nariyasu, YOKOMISE Hiroyasu, UENO Masaki, HABA Reiji, Lung Cancer, 70, (1), 88-93,   2010年10月, [査読有り]
  • Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer, NAKASHIMA Nariyasu, HUANG Cheng-long, LIU Dage, UENO Masaki, YOKOMISE Hiroyasu, Int J Ocol, 37, (3), 687-694,   2010年09月, [査読有り]
  • Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer, Nariyasu Nakashima, Cheng-Long Huang, Dage Liu, Masaki Ueno, Hiroyasu Yokomise, International Journal of Oncology, 37, (3), 687 - 694,   2010年09月, [査読有り]
    Survivin, a member of the inhibitor of apoptosis protein family, affects tumorigenesis. Recently, survivin is reported to be a target of the canonical Wnt pathway, which activates the transcription of various tumor-associated target genes. One hundred and twenty-two non-small cell lung cancers (NSCLCs) were investigated to evaluate survivin gene expression in relation to the expression of Wnt1 (a novel member of the canonical Wnt pathway) and Wnt5a (a novel member of the non-canonical Wnt pathway). The survivin gene expression was evaluated by semi-quantitative RT-PCR. The protein expression of pan-survivin, Wnt1, and Wn5a were investigated by immunohistochemistry. The apoptotic index and the Ki-67 proliferation index were also evaluated. Sixty-four tumors (52.5%) were survivin-high tumors, 65 tumors were Wnt1-high tumors, and 67 tumors (54.9%) were Wnt5a-high tumors. The standardized survivin gene expression significantly correlated with the apoptotic index (P< 0.0001), the Ki-67 proliferation index (P< 0.0001), and patient survival (P=0.0467). Furthermore, the percentage of Wnt1-positive tumor cells significantly correlated with the standardized survivin gene expression (P< 0.0001). In contrast, the percentage of Wnt5a-positive tumor cells did not correlate with the standardized survivin gene expression. As a result, intratumoral Wnt1 expression significantly correlated with the apoptotic index (P< 0.0001), the Ki-67 proliferation index (P< 0.0001), and patient survival (P=0.0355). Intratumoral Wnt1 overexpression could produce more aggressive NSCLCs by induction of survivin.
  • Expression of ERCC1 and class Ⅲ β-tubulin is associated with the survival of resected stage Ⅲ non-small cell lung cancer patients treated with inducition chemoradiotherapy using carboplatin-taxane, Cheng-long Huang, Kyuichi Kadota, Dage Liu, Nariyasu Nakasima, Masaki Ueno, Shinya Ishikawa, Masashi Gotoh, Noriyuki Misaki, Sung-Soo Chang, Hiroyasu Yokomise, Experimental and Therapeutic Medicine, 1, (3), 445 - 451,   2010年05月, [査読有り]
  • 非小細胞肺癌におけるWntシグナルの過剰発現とその制御への試み, 黄政龍, 劉大革, 門田球一, 中野 淳, 石川真也, 山本恭道, 横見瀬裕保, 肺癌, 49, (4), 422-426,   2009年08月, [査読有り]
  • 非小細胞肺癌におけるWntシグナルの過剰発現とその制御への試み, 黄 政龍, 劉 大革, 門田球一, 中野 淳, 石川真也, 山本恭通, 横見瀬裕保, Cheng-long Huang, Dage Liu, Kyuichi Kadota, Jun Nakano, Shinya Ishikawa, Yasumichi Yamamoto, Hiroyasu Yokomise, 肺癌, 49, (4), 422 - 426,   2009年08月
  • Wnt1 overexpression promotes tumour progression in non-small cell lung cancer, Cheng-Long Huang, Dage Liu, Shinya Ishikawa, Takashi Nakashima, Nariyasu Nakashima, Hiroyasu Yokomise, Kyuichi Kadota, Masaki Ueno, EUROPEAN JOURNAL OF CANCER, 44, (17), 2680 - 2688,   2008年11月, [査読有り]
    Background: The Writ gene family is involved in embryogenesis and tumourigenesis. We investigated the clinical significance of Wnt1 expression in non-small cell lung cancer (NSCLC). Method: We studied 216 NSCLC patients. immunohistochemistry was performed to investigate the Wnt1 expression in relation to the expression of beta-catenin and Wnt-targets, including c-Myc, Cyclin D1, VEGF-A and MMP-7. The Ki-67 proliferation index and the intratumoural microvessel density (IMD) were also evaluated. Results: The ratio of tumours with an aberrant P-catenin expression was significantly higher in Wnt1-positive tumours than in Wnt1-negative tumours (p < 0.0001). The Wnt1 expression significantly correlated with the expression of c-Myc (P < 0.0001), Cyclin D1 (p < 0.0001), VEGF-A (p = 0.0160), MMP-7 (p < 0.0001), the Ki-67 index (p = 0.0048) and the IMD (p = 0.0267). Furthermore, the Wnt1 status was a significant prognostic factor for NSCLC patients (p = 0.0127). Conclusions: The Wnt1 overexpression is associated with the expression of tumour-associated Wnt-targets, tumour proliferation, angiogenesis and a poor prognosis in NSCLCs. (C) 2008 Elsevier Ltd. All rights reserved.
  • The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients, Kyuichi Kadota, Cheng-long Huang, Dage Liu, Masaki Ueno, Yoshio Kushida, Reiji Haba, Hiroyasu Yokomise, EUROPEAN JOURNAL OF CANCER, 44, (7), 1057 - 1067,   2008年05月, [査読有り]
    Background: Angiogenesis and lymphangiogenesis have been reported to affect malignant phenotype. Method: We investigated 147 patients with non-small cell lung cancer (NSCLC). Immunohistochemistry using D2-40 was performed to evaluate lymphatic vessel density (LVD), including Micro-LVD (without lumen),Tubal-LVD (with lumen) and lymphatic vessel invasion (LVI). The intratumoural microvessel density (MVD) was evaluated by CD-34 immunostaining. The expressions of vascular endothelial growth factor-A (VEGF-A) and VEGF-C were also studied. Results: Lymphangiogenesis was significantly associated with Micro-LVD (p = 0.0003). The VEGF-C expression was significantly associated with the Micro-LVD (p = 0.0057). In contrast, the VEGF-A expression was significantly associated with the MVD (p = 0.0092). The survival was significantly lower in patients with Micro-LVD-high tumours than in patients with Micro-LVD-low tumours (p = 0.0397). Survival was also significantly lower in patients with MVD-high tumours than in patients with MVD-low tumours (p = 0.0334). A multivariate analysis demonstrated that the Micro-LVD (p = 0.0363) and the MVD (p = 0.0232) were independent prognostic factors for NSCLC patients. Conclusions: Lymphangiogenesis, specifically Micro-LVD and angiogenesis are independently associated with a poor prognosis in NSCLC patients. (c) 2008 Elsevier Ltd. All rights reserved.
  • The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers, J. Nakano, C. Huang, D. Liu, D. Masuya, H. Yokomise, M. Ueno, R. Haba, S. Sumitomo, BRITISH JOURNAL OF CANCER, 98, (6), 1109 - 1117,   2008年03月, [査読有り]
    Survivin is a member of the inhibitor of apoptosis protein family. Survivin has splice variants with different biological functions associated with tumorigenesis. We investigated 134 non- small cell lung cancers ( NSCLCs) to study the clinical significance of wildtype survivin, survivin- 2B, and survivin- deltaEx3. Real- time PCR analyses were performed for their gene expressions. The subcellular localisation of survivin proteins was evaluated by immunohistochemistry. The Ki- 67 proliferation index and the apoptotic index were also evaluated. The survivin- deltaEx3 gene expression was significantly higher in stage II - III than in stage I ( P = 0.0174), and significantly correlated with the nuclear pan- survivin expression ( P < 0.0001). The Ki- 67 index was significantly higher in wild- type survivin- positive tumours ( P < 0.0001), survivin- deltaEx3- positive tumours ( P < 0.0001), and tumours with positive expression of the nuclear pan-survivin ( P =0.0047). In contrast, the apoptotic index was significantly lower only in wild- type survivin- positive tumours ( P < 0.0001). Thus, the wild- type survivin gene expression was associated with apoptotic inhibition and tumour proliferation. Furthermore, the survivin- deltaEx3 gene expression was strongly associated with tumour proliferation, especially in advanced stage NSCLCs. In contrast, the survivin- 2B gene expression did not correlate with tumour proliferation or tumour apoptosis.
  • Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer, Dage Liu, Jun Nakano, Sinya Ishikawaa, Hiroyasu Yokomise, Masaki Ueno, Kyuichi Kadota, Masahide Urushihara, Cheng-long Huang, LUNG CANCER, 58, (3), 384 - 391,   2007年12月, [査読有り]
    Background: Matrix metatloporteinase-7 (MMP-7) is a member of the MMP family, and it has been reported to play an important rote in tumorigenesis, invasion and metastasis. We performed a retrospective study on the MMP-7 expression in non-small cell lung cancer (NSCLC) according to the clinical characteristics, biological markers and the Wnt1 expression. Patients and methods: One hundred forty-seven postsurgical NSCLC patients were investigated. Immunohistochemistry was performed to evaluate the MMP-7 expression, the Ki-67 proliferation index, tumor angiogenesis and the Wnt1 expression. The TUNEL method was performed to investigate tumor apoptosis. Results: Seventy-six carcinomas (51.7%) were MMP-7-positive. The MMP-7 expression was significantly higher in squamous cell carcinomas than in adenocarcinomas (P < 0.0001). The Ki-67 proliferation index was significantly higher in MMP-7-positvie tumors than in MMP-7-negative tumors (P = 0.0003). However, there was no difference in the MMP-7 expression in relation to apoptosis or angiogenesis. Regarding its regulation, the MMP-7 expression significantly correlated with the Wnt1 expression (r = 0.426, P < 0.0001). The overall survival was significantly lower in patients with MMP-7-positive NSCLCs than in those with MMP-7-negative NSCLCs (P=0.0018). A Cox regression analyses also demonstrated MMP-7 status to be a significant prognostic factor (hazard ratio, 2.187; P = 0.0023). Conclusions: The overexpression of MMP-7 was associated with tumor proliferation, and a poor prognosis in NSCLCs. In addition, Wnt1 may play a critical role in regulating the intratumoral MMP-7 expression. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
  • E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non-small-cell lung cancer, Cheng-long Huang, Dage Liu, Jun Nakano, Hiroyasu Yokomise, Masaki Ueno, Kyuichi Kadota, Hiromi Wada, CLINICAL CANCER RESEARCH, 13, (23), 6938 - 6946,   2007年12月, [査読有り]
    Purpose: We investigated the clinical significance of E2F1 gene expression in relation to its target genes, thymidylate synthase (TS) and Survivin, in case of non-small-cell lung cancer (NSCLC). Experimental Design: One hundred twenty-seven cases of resected NSCLC were analyzed. Quantitative reverse transcription-PCR was done to evaluate the gene expression of E2F1, TS, and Survivin. Immunohistochemistry was done to investigate the protein expression of E2F1,TS, and Survivin. The Ki-67 proliferation index and the apoptotic index using the terminal deoxyribonucleotidyl transferase - mediated dUTP nick-end labeling method were also evaluated. Results: E2F1 gene expression significantly correlated with the Ki-67 proliferation index (r = 0.487; P < 0.0001), although no correlation was observed between E2F1 gene expression and the apoptotic index. With regard to E2F1 target genes, E2F1 gene expression significantly correlated with TS gene expression (r = 0.709; P < 0.0001) and Survivin gene expression (r = 0.403; P < 0.0001). The overall survival rate was significantly lower in patients with high-E2F1 tumors than in those with low-E2F1 tumors (P = 0.0027), especially among patients with stage II to III NSCLCs (P = 0.0188). A Cox regression analysis showed that the E2F1 status was a significant prognostic factor for NSCLC patients (hazard ratio, 2.052; P = 0.0261). Conclusions: The present study revealed that E2F1 gene expression correlates with TS and Survivin gene expressions and tumor proliferation. During the progression of NSCLC, E2F1 overexpression could produce more aggressive tumors with a high proliferation rate and chemoresistance.
  • En bloc partial vertebrectomy for lung cancer invading the spine after induction chemoradiotherapy, Hiroyasu Yokomise, Masashi Gotoh, Taku Okamoto, Yasumichi Yamamotoa, Shinya Ishikawa, Dage Liu, Shiro Oka, Cheng-Long Huang, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 31, (5), 788 - 790,   2007年05月, [査読有り]
    Objective: The optimal surgical treatment for non-small cell lung cancer (NSCLC) with vertebral, body invasion remains both controversial and challenging. We reviewed our experiences of NSCLC with vertebral. body invasion, in which we have performed induction chemoradiotherapy followed by lung resection with en bloc partial vertebrectomy. Methods: Six NSCLC patients with vertebral invasion underwent an operation following chemoradiotherapy from January 2001 to July 2006. Vertebral invasion was evaluated by the chest CT and MRI findings. Either carboplatin-paclitaxel (n = 3) or carboplatin-docetaxel (n = 3) was used. Two cycles of chemotherapy were performed with concurrent radiation (50 Gy) treatment. Results: In all of the six cases, a complete resection with en bloc partial vertebrectomy was performed with no operative mortality. The histological complete response rate and major response rate were 16.7% (1/6) and 83.3% (5/6), respectively. The 5-year overall survival rate was 67.7%. In addition, no local failure was observed after surgery. Conclusions: Surgery after chemoradiotherapy (carboplatin/ pactitaxel or docetaxel and 50 Gy radiation) for NSCLC with vertebral invasion could thus be performed with acceptable morbidity. (c) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2, C-L Huang, M. Ueno, D. Liu, D. Masuya, J. Nakano, H. Yokomise, T. Nakagawa, M. Miyake, ONCOGENE, 25, (49), 6480 - 6488,   2006年10月, [査読有り]
    Motility-related protein-1 (MRP-1/CD9) is involved in cell motility. We studied the change in the actin cytoskeleton, and the expression of actin-related protein (Arp) 2 and Arp3 and the Wiskott-Aldrich syndrome protein ( WASP) family according to MRP-1/CD9 gene transduction into HT1080 cells. The frequency of cells with lamellipodia was significantly lower in MRP-1/CD9-transfected HT1080 cells than in control HT1080 cells (P < 0.0001). MRP-1/CD9 gene transduction affected the subcellular localization of Arp2 and Arp3 proteins. Furthermore, MRP-1/CD9 gene transduction induced a downregulation of WAVE2 expression (P < 0.0001). However, no difference was observed in the expression of Arp2, Arp3 or other WASPs. A neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited downregulation of WAVE2 in MRP-1/CD9-transfected HT1080 cells (P < 0.0001 ), and reversed the morphological effects of MRP-1/CD9 gene transduction. Furthermore, downregulation of WAVE2 by transfection of WAVE2-specific small interfering RNA ( siRNA) mimicked the morphological effects of MRP-1/CD9 gene transduction and suppressed cell motility. However, transfection of each siRNA for Wnt1, Wnt2b1 or Wnt5a did not affect WAVE2 expression. Transfection of WAVE2-specific siRNA also did not affect expressions of these Wnts. These results indicate that MRP-1/CD9 regulates the actin cytoskeleton by downregulating of the WAVE2, through the Wnt-independent signal pathway.
  • Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT, J. Nakano, C. Huang, D. Liu, D. Masuya, T. Nakashima, H. Yokomise, M. Ueno, H. Wada, M. Fukushima, BRITISH JOURNAL OF CANCER, 95, (5), 607 - 615,   2006年09月, [査読有り]
    The sensitivity to 5-fluorouracil (5-FU) has been reported to be associated with target molecule thymidylate synthase (TS), fluoropyrimidine-metabolising enzymes such as orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD). We performed an immunohistochemical study on the clinical significance of TS, OPRT, and DPD expression using 151 resected non-small-cell lung cancer (NSCLC) patients postoperatively treated with a combination of tegafur and uracil (UFT). Eighty-two carcinomas were TS-positive, 105 carcinomas were OPRT-positive, 68 carcinomas were DPD-positive. No correlation was observed in the HSCORE between the TS and OPRT expression (r = 0.203), between the TS and DPD expression (r = 0.098), or between the OPRT and DPD expression (r = 0.074). Regarding the survival of NSCLC patients treated with UFT, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that with TS-positive tumours (P = 0.0133). The 5-year survival rate of patients with OPRT-positive stage II to III tumours was significantly higher than that with OPRT-negative stage II to III tumours (P = 0.0145). In addition, the 5-year survival rate of patients with DPD-negative tumours was also significantly higher than that with DPD-positive tumours (P = 0.0004). A Cox multivariate regression analysis revealed the TS status (hazard ratio 2.663; P = 0.0003), OPRT status (hazard ratio 2.543; P = 0.0005), and DPD status (hazard ratio 2.840; P < 0.0001) to all be significant prognostic factors for the survival of resected NSCLC patients postoperatively treated with UFT.
  • A useful protocol for analyses of mutations of the epidermal growth factor receptor gene, D Liu, J Nakano, M Ueno, D Masuya, T Nakashima, H Yokomise, K Yube, CL Huang, ONCOLOGY REPORTS, 15, (6), 1503 - 1505,   2006年06月
    Recent studies have reported that mutations of the epidermal growth factor receptor (EGFR) gene are associated with the responsiveness of tyrosine kinase inhibitors (TKIs), which are molecular targets for non-small cell lung cancer (NSCLC). To provide genetic analyses for NSCLC patients, a simple and reliable method using paraffin-embedded materials is needed. The DEXPAT DNA extraction kit was used for DNA extraction from paraffin-embedded materials. DNA was amplified using the nested PCR technique, then analyzed by direct sequencing for EGFR mutations (exons 18 to 21). The phenol/chloroform extraction for DNA was also performed for comparison. When the DEXPAT kit was used, distinct bands were observed in all products after nested PCR assays of paraffin-embedded materials. Distinct sequencing signals were obtained. Results from the sequencing analysis of paraffin-embedded materials and frozen materials were completely concordant. The current study suggests that DNA extraction with the DEXPAT kit followed by nested PCR is a simple and reliable technique for analyzing the EGFR gene status with paraffin-embedded samples.
  • Large cell carcinoma with neuroendocrine morphology of the lung, Daiki Masuya, Dage Liu, Shinya Ishikawa, Yasumichi Yamamoto, Cheng-Long Huang, Hiroyasu Yokomise, Japanese Journal of Thoracic and Cardiovascular Surgery, 54, (1), 31 - 34,   2006年01月, [査読有り]
    We experienced a surgical case of large cell carcinoma with neuroendocrine morphology (LCCNM) of the lung. A 76-year-old man was admitted to our hospital because a routine chest X-ray examination had revealed a nodular shadow in the left lung field. 18F-fluorodeoxyglucose positron emission tomography showed accumulation of fluorodeoxyglucose in an area corresponding to the shadow. Transbronchial lung biopsy failed to give a definitive diagnosis, therefore open lung biopsy was performed because of suspected lung cancer. Needle biopsy was performed, and the tumor was diagnosed as large cell neuroendocrine carcinoma by rapid intraoperative pathological examination. As sampling of hilar lymph nodes revealed no metastasis, left upper segmentectomy was performed for severe obstructive pulmonary disease. Immunohistochemical examination finally diagnosed the tumor as LCCNM. The patient is doing well without recurrence at ten months after surgery.
  • Therapeutic strategy based on biological markers for non-small-cell lung cancers, Cheng-long Huang, Hiroyasu Yokomise, Dage Liu, Enhancer-Biotherapy of Cancer, 4, (1), 19-21,   2006年
  • Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor - An expression in non-small-cell lung cancer, CL Huang, D Liu, J Nakano, S Ishikawa, K Kontani, H Yokomise, M Ueno, JOURNAL OF CLINICAL ONCOLOGY, 23, (34), 8765 - 8773,   2005年12月
    Purpose The Writ gene family encodes the multifunctional signaling glycoproteins. We performed the present study to investigate the clinical significance of Wnt5a expression in non-small-cell lung cancer (NSCLC). Patients and Methods One hundred twenty-three patients with NSCLC who had undergone resection were investigated. Real-time quantitative reverse transcriptase polymerase chain reaction was performed to evaluate the Wnt5a gene expression. Immunohistochemistry was performed to investigate the Wnt5a protein expression, the Ki-67 proliferation index, tumor angiogenesis, and the expression of beta-catenin and vascular endothelial growth factor-A (VEGF-A). Results Wnt5a gene expression in squamous cell carcinoma was significantly higher than that in adenocarcinoma (P < .0001). There was a significant correlation between the normalized Wnt5a gene expression ratio and the intratumoral Wnt5a protein expression (r = 0.729; P < .0001). The intratumoral Wnt5a expression was significantly correlated with the Ki-67 proliferation index (r = 0.708; P < .0001). In contrast, no correlation was observed between the intratumoral Wnt5a expression and tumor angiogenesis. Furthermore, the intratumoral Wnt5a expression was significantly correlated with the stromal expression of beta-catenin (r = 0.729; P < .0001) and VEGF-A (r = 0.661; P < .0001). In addition, the stromal VEGF-A expression was also correlated with Ki-67 proliferation (r = 0.627; P < .0001). Cox regression analyses demonstrated Wnt5a status to be a significant prognostic factor for NSCLC patients (P = .0193), especially for patients with squamous cell carcinomas (P = .0491). Conclusion The present study revealed that an overexpression of Wnt5a could produce more aggressive NSCLC, especially in squamous cell carcinomas, during tumor progression.
  • Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer, J Nakano, CL Huang, DG Liu, M Ueno, S Sumitomo, H Yokomise, INTERNATIONAL JOURNAL OF ONCOLOGY, 27, (5), 1215 - 1221,   2005年11月
    Survivin is considered to be associated with tumorigenesis by regulating apoptosis and cell proliferation. Recent experimental studies reported survivin gene expression to be negatively regulated by wild-type p53. We investigated resected tumor specimens from 140 non-small cell lung cancer (NSCLC) patients. Quantitative reverse-transcription PCR analysis was performed to evaluate survivin gene expression. PCR-single strand conformation polymorphism following sequencing was performed to investigate mutations of p53. The apoptotic index and the Ki-67 proliferation index were also evaluated according to the survivin expression. The survivin expression was low in normal lung tissue. In contrast, the survivin expression varied greatly among tumor tissues. The survivin expression in squamous cell carcinomas was significantly higher than that in adenocarcinomas (P=0.0109). The survivin expression in moderately or poorly differentiated tumors was significantly higher than that in well-differentiated tumors (P=0.0334). Furthermore, the survivin expression in tumors with mutant p53 was significantly higher than that in tumors with wild-type p53 (P=0.0026). In addition, the apoptotic index was significantly lower in high-survivin tumors than in low-survivin tumors (P < 0.0001). The Ki-67 proliferation index was significantly higher in high-survivin tumors than in low-survivin tumors (P < 0.0047). This study indicated survivin gene expression to be negatively regulated by p53 in NSCLC, and that survivin expression could inhibit apoptosis and accelerate tumor cell proliferation to produce more aggressive carcinomas.
  • Clinical application of biological markers for treatments of resectable non-small-cell lung cancers, C Huang, D Liu, D Masuya, T Nakashima, K Kameyama, S Ishikawa, M Ueno, R Haba, H Yokomise, BRITISH JOURNAL OF CANCER, 92, (7), 1231 - 1239,   2005年04月
    We performed a clinical study to identify biological markers useful for the treatment of resectable non-small-cell lung cancers (NSCLCs). In all, 173 patients were studied. By immunohistochemistry, we evaluated the Ki-67 proliferation index, tumour vascularity, thymidylate synthase (TS), vascular endothelial growth factor ( VEGF)-A, VEGF-C, and E ( epithelial)-cadherin. Concerning the survival of NSCLC patients, tumour vascularity (P<0.01), VEGF-A status ( P = 0.03), VEGF-C status ( P = 0.03), and E-cadherin status ( P = 0.03) were significant prognostic factors in patients with stage I NSCLCs. The Ki-67 proliferation index ( P = 0.02) and TS status (P<0.01) were significant prognostic factors in patients with stage II - III NSCLCs. In patients with stage II - III NSCLCs, furthermore, the survival of UFT ( a combination of tegafur and uracil)- treated patients with TS-negative tumours was significantly better than those of any other patients. Biological markers associated with tumour angiogenesis or metastasis are useful for the detection of aggressive tumours among early-stage NSCLCs. Postoperative chemotherapy might be necessary in such tumours even in stage I. In contrast, tumour proliferation rate and TS status are useful markers for identifying less aggressive tumours in locally advanced NSCLCs. Thymidylate synthase expression is also a useful marker to evaluate responsiveness of UFT-based chemotherapy for these tumours.
  • MRP-1/CD9 gene transduction downregulates Wnt signal pathways, CL Huang, DG Liu, D Masuya, K Kameyama, T Nakashima, H Yokomise, M Ueno, M Miyake, ONCOGENE, 23, (45), 7475 - 7483,   2004年09月
    Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/ CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/ CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/ CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.
  • MRP-1/CD9 gene transduction downregulates Wnt signal pathways, CL Huang, DG Liu, D Masuya, K Kameyama, T Nakashima, H Yokomise, M Ueno, M Miyake, ONCOGENE, 23, (45), 7475 - 7483,   2004年09月
    Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/ CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/ CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/ CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.
  • The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients, D Masuya, C Huang, D Liu, T Nakashima, K Kameyama, R Haba, M Ueno, H Yokomise, BRITISH JOURNAL OF CANCER, 90, (8), 1555 - 1562,   2004年04月
    Immunohistochemical analyses of the effects of hepatocyte growth factor (HGF) and c-Met expression on tumour growth and angiogenesis were performed on 88 patients with non-small-cell lung cancers (NSCLCs). In all, 22 carcinomas (25.0%) were intratumoral HGF-positive, 14 carcinomas (15.9%) were stromal HGF-positive, and 36 carcinomas (40.9%) were intratumoral c-Met-positive. None of the carcinomas were stromal c-Met-positive. Examination of tumour growth revealed that the frequency of tumours with a high Ki-67 index was significantly greater for stromal HGF-positive tumours than for stromal HGF-negative tumours (P = 0.0197). The frequency of tumours with a high Ki-67 index was also significantly greater for intratumoral c-Met-positive tumours than for intratumoral c-Met-negative tumours (P = 0.0301). However, there was no significant difference in tumour vascularity with relation to intratumoral HGF status, stromal HGF status, and intratumoral c-Met status. The survival rate of patients with intratumoral c-Met-positive tumours was significantly lower than for patients with c-Met-negative tumours (P = 0.0095). Furthermore, the survival rate of patients with both intratumoral c-Met-positive and stromal HGF-positive tumours was significantly lower than for patients with either positive tumours, and that of patients with both negative tumours (P = 0.0183 and P = 0.0011, respectively). A univariate analysis revealed that intratumoral c-Met expression was a significant prognostic factor of NSCLC patients (relative risk = 2.642, P = 0.0029). The present study demonstrates that tumour-stromal interaction between tumour cell-derived c-Met and stromal cell-derived HGF affects tumour growth and the prognosis of NSCLC patients.
  • The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients, D Masuya, C Huang, D Liu, T Nakashima, K Kameyama, R Haba, M Ueno, H Yokomise, BRITISH JOURNAL OF CANCER, 90, (8), 1555 - 1562,   2004年04月
    Immunohistochemical analyses of the effects of hepatocyte growth factor (HGF) and c-Met expression on tumour growth and angiogenesis were performed on 88 patients with non-small-cell lung cancers (NSCLCs). In all, 22 carcinomas (25.0%) were intratumoral HGF-positive, 14 carcinomas (15.9%) were stromal HGF-positive, and 36 carcinomas (40.9%) were intratumoral c-Met-positive. None of the carcinomas were stromal c-Met-positive. Examination of tumour growth revealed that the frequency of tumours with a high Ki-67 index was significantly greater for stromal HGF-positive tumours than for stromal HGF-negative tumours (P = 0.0197). The frequency of tumours with a high Ki-67 index was also significantly greater for intratumoral c-Met-positive tumours than for intratumoral c-Met-negative tumours (P = 0.0301). However, there was no significant difference in tumour vascularity with relation to intratumoral HGF status, stromal HGF status, and intratumoral c-Met status. The survival rate of patients with intratumoral c-Met-positive tumours was significantly lower than for patients with c-Met-negative tumours (P = 0.0095). Furthermore, the survival rate of patients with both intratumoral c-Met-positive and stromal HGF-positive tumours was significantly lower than for patients with either positive tumours, and that of patients with both negative tumours (P = 0.0183 and P = 0.0011, respectively). A univariate analysis revealed that intratumoral c-Met expression was a significant prognostic factor of NSCLC patients (relative risk = 2.642, P = 0.0029). The present study demonstrates that tumour-stromal interaction between tumour cell-derived c-Met and stromal cell-derived HGF affects tumour growth and the prognosis of NSCLC patients.
  • Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer, Med Sci Monit, 10, (6), BR157-BR165,   2004年
  • E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer, Ann Thorac Surg, 71, 949 - 955,   2001年
  • 気管軟骨の構造特性:成長に伴う物理生化学的変化, 劉 大革(LIU Dage, 日本呼吸器外科学会雑誌, 13, (4), 494-502,   1999年05月, [査読有り]

講演・口頭発表等

  • 非小細胞肺癌におけるアミノ酸トランスポーターSLC7A11/xCT発現の臨床意義, 劉 大革, 中島 成泰, 中野 貴之, 張 霞, 横見瀬 裕保, 77回日本癌学会学術総会,   2018年09月30日
  • 非小細胞肺癌におけるオートファジーの臨床的意義, 劉大革, 中島成泰, 中野貴之, 芳賀ななせ, 加藤 歩, 横田直也, 藤原敦史, 松浦奈津美, 垂水晋太郎, 張 性洙, 呉 哲彦, 横見瀬裕保, 第35回呼吸器外科学会,   2018年05月17日
  • 非小細胞肺癌における抗癌剤耐性遺伝子を標的とした遺伝子治療の基礎研究, 劉 大革, 中島 成泰, 中野 貴之, 喜田 裕介, 徳永 義昌, 張 霞, 呉 哲彦, 黄 政龍, 横見瀬 裕保, 第76回日本癌学会学術総会,   2017年09月29日
  • 非小細胞肺癌における抗癌剤耐性遺伝子を標的とした遺伝子治療の検討, 第33回日本呼吸器外科学会総会,   2016年
  • 非小細胞肺癌の抗癌剤感受性試験(CD-DST法)と抗癌剤耐性関連バイオマーカーの相関性に関する検討, 第33回日本呼吸器外科学会総会,   2016年
  • Verification of biomarkers in predicting drug sensitivity with in vitro 3D drug sensitivity test in non-small cell lung cancer tumor, 2016 Annual Meeting of American Society of Clinical Oncology (ASCO),   2016年
  • Correlation among the biomarkers for oral anti-cancer agents in lung adenocarcinoma, 2016 Annual Meeting of American Society of Clinical Oncology (ASCO),   2016年
  • MCL1遺伝子抑制はMCL1 遺伝子発現非小細胞肺癌株の増殖抑制とDOC感受性向上を引き起こす, 第75回日本癌学会学術総会,   2016年
  • RRM1抑制アデノウィルスベクターによる悪性中皮腫RRM1発現細胞株の増殖抑制の研究, 第75回日本癌学会学術総会,   2016年
  • 肺癌細胞株におけるGPR87抑制アデノウイルスベクターの抗細胞増殖効果, 第75回日本癌学会学術総会,   2016年
  • RRM1高発現膀胱癌細胞株におけるRRM1抑制アデノウィルスベクターの抗細胞増殖効果, 第75回日本癌学会学術総会,   2016年
  • 非小細胞肺癌における抗癌剤耐性遺伝子を標的とした遺伝子治療の検討, 第33回日本呼吸器外科学会総会,   2016年
  • 非小細胞肺癌の抗癌剤感受性試験(CD-DST法)と抗癌剤耐性関連バイオマーカーの相関性に関する検討, 第33回日本呼吸器外科学会総会,   2016年
  • Verification of biomarkers in predicting drug sensitivity with in vitro 3D drug sensitivity test in non-small cell lung cancer tumor, 2016 Annual Meeting of American Society of Clinical Oncology (ASCO),   2016年
  • Correlation among the biomarkers for oral anti-cancer agents in lung adenocarcinoma, 2016 Annual Meeting of American Society of Clinical Oncology (ASCO),   2016年
  • siRNA targeting MCL1 inhibit cell proliferation and increase DOC-sensitinity in MCL1-overexpressing lung cancer cells, 第75回日本癌学会学術総会,   2016年
  • RRM1抑制アデノウィルスベクターによる悪性中皮腫RRM1発現細胞株の増殖抑制の研究, 第75回日本癌学会学術総会,   2016年
  • 肺癌細胞株におけるGPR87抑制アデノウイルスベクターの抗細胞増殖効果, 第75回日本癌学会学術総会,   2016年
  • Adenoviral shRNA vector targeting RRM1 inhibits cancer cell growth in RRM1-overexpressing bladder cancer cells, 第75回日本癌学会学術総会,   2016年
  • RRM1抑制アデノウィルスベクターによるRRM1発現肺癌細胞への抗腫瘍作用, 第74回日本癌学会学術総会,   2015年
  • ヒト膀胱癌細胞株における新規化合物uvedafolinの抗腫瘍効果, 第74回日本癌学会学術総会,   2015年
  • Adenoviral shRNA vector targeting RRM1 exerts a strong antitumor activity against RRM1 expressing lung cancer cells, 第74回日本癌学会学術総会,   2015年
  • Anti-tumor activity of uvedafolin in human bladder cancer cell lines, 第74回日本癌学会学術総会,   2015年
  • Effect of Adenoviral Vector Expressing Short Hairpin siRNA Targeting RRM1 Gene on Cell Viability and Chemosensitivity to Gemcitabin in Human Non-small Cell Lung Cancer Cells, Drug Discovery & Therapy World Congress 2014 (DDTWC2014),   2014年
  • RRM1抑制アデノウィルスベクターによる癌遺伝子治療の基礎的研究, 第73回日本癌学会学術総会,   2014年
  • 前立腺癌細胞株におけるGPR87抑制アデノウイルスベクターの抗腫瘍効果, 第72回日本癌学会学術総会,   2014年
  • Effect of Adenoviral Vector Expressing Short Hairpin siRNA Targeting RRM1 Gene on Cell Viability and Chemosensitivity to Gemcitabin in Human Non-small Cell Lung Cancer Cells, Drug Discovery & Therapy World Congress 2014 (DDTWC2014),   2014年
  • In vitro experiment on cancer gene therapy using the RRM1-suppressing adenoviral vector, 第73回日本癌学会学術総会,   2014年
  • Anti-tumor activity of GPR87-suppressing adenovirual vector in human prostate cancer cell lines, 第72回日本癌学会学術総会,   2014年
  • Association of tumor-specific GPR87 overexpression with poor prognosis in non-small cell lung cancer, 2013 Annual Meeting of American Society of Clinical Oncology (ASCO),   2013年
  • RRM1抑制アデノウィルスベクターによる癌遺伝子治療の基礎的研究, 第72回日本癌学会学術総会,   2013年
  • 前立腺癌細胞株におけるエンヒドリンの抗腫瘍効果, 第72回日本癌学会学術総会,   2013年
  • Association of tumor-specific GPR87 overexpression with poor prognosis in non-small cell lung cancer, 2013 Annual Meeting of American Society of Clinical Oncology (ASCO),   2013年
  • In vitro experiment on cancer gene therapy using the RRM1-suppressing adenoviral vector, 第72回日本癌学会学術総会,   2013年
  • Anti-tumor activity of enhydrin in human prostate cancer cell lines, 第72回日本癌学会学術総会,   2013年
  • 肺腺癌術後症例におけるバイオマーカーの検索及び術後治療効果との関連, 第112回日本外科学会定期学術集会,   2012年
  • 非小細胞肺癌における新規p53標的遺伝子DNA polymerase η(PolH)発現の臨床意義, 第71回日本癌学会学術総会,   2012年
  • The correlation between the tumor biomarkers and clinical output in post-operative patients with lung adenocarcinoma, 第112回日本外科学会定期学術集会,   2012年
  • The clinical role of the novel p53 target gene DNA polymerase η(PolH) expression in non-small cell lung cancer, 第71回日本癌学会学術総会,   2012年
  • Wnt2B高発現腫瘍に対するWnt2B抑制アデノウィルスベクターの抗腫瘍効果, 第70回日本癌学会学術総会,   2011年
  • GPR87高発現癌細胞株に対するGPR87抑制アデノウイルスベクターのp53依存性抗腫瘍効果, 第70回日本癌学会学術総会,   2011年
  • Wnt2B-suppressing adenoviral vector has a significant antitumor activity against Wnt2B-overexpressing tumors, 第70回日本癌学会学術総会,   2011年
  • GPR87-suppressing adenoviral vector suppressed viability of GPR87-overexpressing bladder cells in a p53-dependent way, 第70回日本癌学会学術総会,   2011年
  • 非小細胞肺癌におけるWnt2Bのc-Myc非発現誘導とその臨床的意義, 第27回日本呼吸器外科学会総会,   2010年
  • 肺線癌術後症例におけるバイオマーカーの検索及び予後, 第28回日本呼吸器外科学会総会,   2010年
  • 非小細胞肺癌におけるWnt2BのcMyc発現誘導とその臨床意義, 第69回日本癌学会学術総会,   2010年
  • 非小細胞肺癌における腫瘍内Wnt1発現のsurvivin発現への関連, 第69回日本癌学会学術総会,   2010年
  • 非小細胞肺癌におけるWnt2Bのc-Myc非発現誘導とその臨床的意義, 第27回日本呼吸器外科学会総会,   2010年
  • The intratumoral Wnt1 expression affects survivin expression in non-small cell lung cancer, 第69回日本癌学会学術総会,   2010年
  • Adenoviral vector expressing short hairpin RNA targeting Wnt2b has a strong antitumor activity against Wnt2b-overexpressing tumors, AACR 100th Annual Meeting 2009,   2009年
  • Wnt2B高発現癌細胞株に対するWnt2B抑制アデノウイルスベクターの抗腫瘍効果, 第68回日本癌学会学会総会,   2009年
  • Wnt overexpression in lung cancer and Wnt-inhibiting cancer gene therapy, BIT's 7th Annual Congress of IDDST,   2009年
  • Wnt2B-suppressing adenoviral vector suppressed the viability of Wnt2B-overexpressing tumor cells, The 19th HCS- The 3rd Three Universities' Consortium International Symposium,   2009年
  • Wnt2B-suppressing adenoviral vector suppressed the viability of Wnt2B-overexpressing tumor cells, 第68回日本癌学会学会総会,   2009年
  • Wnt overexpression in lung cancer and Wnt-inhibiting cancer gene therapy, BIT's 7th Annual Congress of IDDST,   2009年
  • Wnt2B-suppressing adenoviral vector suppressed the viability of Wnt2B-overexpressing tumor cells, The 19th HCS- The 3rd Three Universities' Consortium International Symposium,   2009年
  • Wnt1 overexpression is associated with tumor proliferation and angiogenesis in non-small cell lung cancer, Annual Meeting of American Association fo Cancer Research,   2008年
  • Wnt2B抑制アデノウィルスベクターによる癌遺伝子治療の基礎的研究, 第67回日本癌学会学会総会,   2008年
  • Wnt1 overexpression is associated with tumor proliferation and angiogenesis in non-small cell lung cancer, Annual Meeting of American Association fo Cancer Research,   2008年
  • 非小細胞肺癌におけるTSとsurvivinの遺伝子発現に関連するE2F1過剰発現, 2007 Annual Meeting of American Society of Clinical Oncology,   2007年
  • 非小細胞肺癌におけるWnt1過剰発現の臨床的意義, 第66回日本癌学会学会総会,   2007年
  • E2F1 overexpression associated with TS and survivin gene expressions in non-small cell lung cancer, 2007 Annual Meeting of American Society of Clinical Oncology,   2007年
  • 非小細胞肺癌における腫瘍内Wnt5a発現とtumor-stromal interaction, 第106回日本外科学会定期学術集会,   2006年
  • 非小細胞肺癌におけるバイオマーカーに基づいた個別化アジュバント化学療法, 第23回日本呼吸器外科学会総会,   2006年
  • Wnt signal pathways are down-regulated by MRP-1/CD9 gene transduction, 96th Annual Meeting of American Association for Cancer Research,   2005年
  • survivin gene expression is negativily regurated by p53 tumor suppressor gene in non-small cell lung cancer, American Association of Caner Reserch,   2005年
  • 分子マーカーに基づく非小細胞肺癌の治療戦略, 第22回日本呼吸器外科学会総会,   2005年
  • MRP-1/CD9遺伝子導入によるWntシグナル抑制, 第64回日本癌学会学術総会,   2005年
  • 分子マーカーに基づいた非小細胞肺癌のオーダーメイド化学療法, 第58回日本胸部外科学会定期学術集会,   2005年
  • Wnt signal pathways are down-regulated by MRP-1/CD9 gene transduction, 96th Annual Meeting of American Association for Cancer Research,   2005年
  • survivin gene expression is negativily regurated by p53 tumor suppressor gene in non-small cell lung cancer, American Association of Caner Reserch,   2005年
  • Clinical application of biological markers for treatments of non-small cell lung cancer patients, 9th World Congress on Advances in Oncology,   2004年
  • Clinical application of biological markers for treatments of non-small cell lung cancer patients, 9th World Congress on Advances in Oncology,   2004年

受賞

  •   2005年, 優秀演題賞

競争的資金

  • 非小細胞肺癌における抗癌剤耐性遺伝子を標的とした遺伝子治療の検討,   2010年
  • Study on gene therapy targeting the drug-resistant genes in non-small cell lung cancer,   2010年
  • short hair-pin siRNA Adeno virus vectorによる肺癌遺伝子治療の試み,   2006年
  • Gene Therapy withshort hair-pin siRNA Adeno virus vector for lung cancer,   2006年
  • 非小細胞肺癌におけるWnt遺伝子発現の臨床意義,   2005年
  • 非小細胞肺癌における個別化治療 (テーラーメード医療),   2005年
  • The clininical role of Wnt family in the NSCLC,   2005年
  • personalized medicine in NSCLC (tailor-made medicine ),   2005年
  • 肺癌における包括的遺伝子診断,   2002年
  • Comprehensive gene dignosis in lung cancer,   2002年